Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Cellestia Biotech AG
- Target Recruit Count
- 79
- Registration Number
- NCT03422679
- Locations
- π¨π
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
πͺπΈVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath